Telix Pharmaceuticals Limited (TLX)

Market Cap	2.32B -60.1%
Revenue (ttm)	664.23M +55.3%
Net Income	10.84M -66.8%
EPS	0.04 -45.2%
Shares Out	338.40M
PE Ratio	163.23
Forward PE	116.19
Dividend	n/a
Ex-Dividend Date	n/a

Volume	168,147
Open	7.03
Previous Close	7.13
Day's Range	6.87 - 7.13
52-Week Range	6.87 - 30.36
Beta	1.22
Analysts	Strong Buy
Price Target	21.00 (+201.72%)
Earnings Date	Jan 19, 2026

About TLX

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 423
• Stock Exchange: NASDAQ
• Ticker Symbol: TLX
• Website: https://telixpharma.com

Financial Performance

In 2024, Telix Pharmaceuticals's revenue was $484.69 million, an increase of 41.49% compared to the previous year's $342.57 million. Earnings were $30.89 million, an increase of 769.68%.

Analyst Summary

According to 4 analysts, the average rating for TLX stock is "Strong Buy." The 12-month stock price target is $21.0, which is an increase of 201.72% from the latest price.

Price Target

$21.0

(201.72% upside)

Analyst Consensus: Strong Buy